Praxis Precision Medicines to Present at Upcoming Investor Conferences
July 06 2021 - 9:00AM
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage
biopharmaceutical company translating genetic insights into the
development of therapies for central nervous system (CNS) disorders
characterized by neuronal imbalance, today announced that
management will participate in the following upcoming virtual
investor conferences:
- Cowen Psychedelics &
Novel Mechanisms in Neuropsychiatry SummitFireside chat on
Tuesday, July 13, 2021 at 3:00 p.m. ET
- William Blair Biotech Focus
Conference 2021‘Updates in Neuropsych’ panel on Thursday,
July 15, 2021 at 12:00 p.m. ET
The events will be available via webcast through the Events
& Presentations page of the Investors + Media section of the
company’s website at www.praxismedicines.com. Replays of the
webcasts will be available for 90 days following the events.
About PraxisPraxis Precision Medicines is a
clinical-stage biopharmaceutical company translating genetic
insights into the development of therapies for central nervous
system disorders (CNS) characterized by neuronal imbalance. Praxis
is applying insights from genetic epilepsies to broader
neurological and psychiatric disorders, using our understanding of
shared biological targets and circuits in the brain. Praxis has
established a broad portfolio, including multiple disclosed
programs across CNS disorders including depression, epilepsy,
movement disorders and pain syndromes, with three clinical-stage
product candidates. For more information, please
visit www.praxismedicines.com and follow us
on LinkedIn and Twitter.
Investor Contact:
Alex Kane
Praxis Precision Medicines
investors@praxismedicines.com
617-300-8481
Media Contact:
Ian Stone
Canale Communications
Ian.stone@canalecomm.com
619-849-5388
Praxis Precision Medicines (NASDAQ:PRAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Praxis Precision Medicines (NASDAQ:PRAX)
Historical Stock Chart
From Apr 2023 to Apr 2024